Royal London Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Royal London Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-84,918	Closed	-$563K	–	665
2018 Q4	$563K	Buy	+84,918	New	+$688K	﹤0.01%	650
2014 Q4	$8.86K	Buy	145,986 +74,215	+103%	+$598K	0.02%	503
2014 Q3	$723K	Hold	71,771	–	–	0.02%	510
2014 Q2	$834K	Sell	71,771 -2,772	-4%	-$29.8K	0.02%	559
2014 Q1	$772K	Buy	+74,543	New	+$953K	0.02%	566

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal London Asset Management's LXRX Position: Q1 2019 in Review

Royal London Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2019, closing a stake of 84,918 shares — an estimated $563K sold.

Royal London Asset Management first reported a position in LXRX in Q1 2014 and held it in 5 quarters. The position peaked at $834K in Q2 2014. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

Royal London Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Royal London Asset Management sold 84,918 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $563K.
Royal London Asset Management first reported a position in Lexicon Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Royal London Asset Management's Lexicon Pharmaceuticals position peaked at $834K in Q2 2014.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on Royal London Asset Management's 13F filing for Q1 2019, filed 30 Apr 2019.